Human Oncology & Pathogenesis Program

The Sarat Chandarlapaty Lab

Share
Back to top

Research

Pictured: Sarat Chandarlapaty
Sarat Chandarlapaty, MD, PhD
Patricia and James Cayne Chair for Junior Faculty

My lab focuses on understanding the regulation of growth factor signal transduction pathways that are aberrantly activated in cancers, with a focus on those implicated in breast cancer pathogenesis.

View Lab Overview

Chandarlapaty Lab

Publications

Li Q, Jiang B, Guo J, Shao H, Del Priore IS, Chang Q, Kudo R, Li Z, Razavi P, Liu B, Boghossian AS, Rees MG, Ronan MM, Roth JA, Donovan KA, Palafox M, Reis-Filho JS, de Stanchina E, Fischer ES, Rosen N, Serra V, Koff A, Chodera JD, Gray NS, Chandarlapaty S. INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors. Cancer Discov. 2022 Feb;12(2):356-371. doi: 10.1158/2159-8290.CD-20-1726. Epub 2021 Sep 20.

Smith AE, Ferraro E, Safonov A, Morales CB, Lahuerta EJA, Li Q, Kulick A, Ross D, Solit DB, de Stanchina E, Reis-Filho J, Rosen N, Arribas J, Razavi P, Chandarlapaty S. HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway. Nat Commun. 2021 Nov 18;12(1):6667. doi: 10.1038/s41467-021-27093-y.

Razavi P, Dickler MN, Shah PD, Toy W, Brown DN, Won HH, Li BT, Shen R, Vasan N, Modi S, Jhaveri K, Caravella BA, Patil S, Selenica P, Zamora S, Cowan AM, Comen E, Singh A, Covey A, Berger MF, Hudis CA, Norton L, Nagy RJ, Odegaard JI, Lanman RB, Solit DB, Robson ME, Lacouture ME, Brogi E, Reis-Filho JS, Moynahan ME, Scaltriti M, Chandarlapaty S. (2020). Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nat Cancer, Mar;1(4):382–393.

Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, Hsieh W, Sanchez-Vega F, Brown DN, Da Cruz Paula AF, Morris L, Selenica P, Eichenberger E, Shen R, Schultz N, Rosen N, Scaltriti M, Brogi E, Baselga J, Reis-Filho JS, Chandarlapaty S. (2018). Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. Cancer Cell, Dec;34(6):893-905.

Will M, Qin AC, Toy W, Yao Z, Rodrik-Outmezguine V, Schneider C, Huang X, Monian P, Jiang X, de Stanchina E, Baselga J, Liu N, Chandarlapaty S*, Rosen N.* (2014). Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer Discov, Mar;4(3):334-47.

View All Publications

People

Pictured: Sarat Chandarlapaty

Sarat Chandarlapaty, MD, PhD

Patricia and James Cayne Chair for Junior Faculty

  • Physician-scientist Sarat Chandarlapaty studies the regulation of growth factor signaling networks in cancer.
  • MD, Wake Forest School of Medicine
  • PhD, University of North Carolina
[email protected]
Email Address
View physician profile
Physician profile

Members

Yanyan Cai

Senior Research Scientist

Wanyi Chen
Wanyi Chen

Graduate Student

Joshua Drago

Assistant Attending

Avantika Gupta
Avantika Gupta

Research Scholar

Catherine S. Jones

Research Technician

Rei Kudo
Rei Kudo

Research Fellow

Minna Lee

Assistant Attending

Qing Li
Qing Li

Research Fellow

Antonio Marra

Research Associate

Elizabeth O'Connell

Research Technician

Payal Patel

Graduate Student

Hong Shao

Research Lab Manager

Marie Will

Assistant Attending

Lab Alumni
Trusha Bhatt
Trusha Bhatt

Research Technician

Isabella Del Priore
Isabella Del Priore

Research Technician

Madeline Dorso
Madeline Dorso

Graduate Student

Mayur Gadiya
Mayur Gadiya

Graduate Student

Kinisha Gala
Kinisha Gala
Seema Irani
Seema Irani
Jisun Kim

Visiting Investigator

Zhiqiang Li
Zhiqiang Li

Research Fellow

Bo Liu, Research Associate
Bo Liu

Research Associate

Shraddha Pancholi
Shraddha Pancholi

Research Secretary

Ramya Segu Rajappachetty
Ramya Segu Rajappachetty

Research Technician Sr.

Alison Smith
Alison Smith

Graduate Student

Antonio Strillacci
Antonio Strillacci

Research Fellow

Weiyi Toy
Weiyi Toy

Research Fellow

Sharmeen Uddin
Sharmeen Uddin

Research Technician

ChengCheng Yang
ChengCheng Yang

Graduate Research Assistant

Lab Affiliations

Achievements

Clinical Investigator Award, Damon Runyon Cancer Research Foundation (2012)

Young Investigator Award, American Society of Clinical Oncology (2007)

Fellow in Biomedical Research, The Dana Foundation (2006)

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Career Opportunities

Apply now

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Sarat Chandarlapaty discloses the following relationships and financial interests:

  • Breast Cancer Research Foundation
    Provision of Services
  • Eli Lilly and Company
    Provision of Services
  • Global Breast Cancer Conference
    Provision of Services (uncompensated)
  • Inivata, Inc.
    Provision of Services
  • Korean Society for Medical Oncology (KSMO)
    Provision of Services
  • Novartis
    Provision of Services
  • Sanofi US Services Inc.
    Provision of Services
  • Targeted Oncology
    Provision of Services
  • The Japanese Breast Cancer Society
    Provision of Services
  • Totus Medicines Inc.
    Ownership / Equity Interests

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures